Association of thiazolidinedione with a lower risk of Parkinson’s disease in a population with newly-diagnosed diabetes mellitus

Hsiu Li Lin, Hsiu Chen Lin, Yuan Fu Tseng, Jane Chen Jui Chao, Chien Yeh Hsu

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Objectives: We investigated the association of thiazolidinedione and its dose effect with the risk of Parkinson’s disease (PD) in patients with diabetes mellitus (DM). Methods: This study enrolled 38,521 patients with newly-diagnosed DM, between 2001 and 2013, and compared them to the matched subjects without DM. The hazard ratios (HRs) for PD were compared between the thiazolidinedione-treated and non-thiazolidinedione-treated groups of the study cohort, and between subgroups who received different cumulative dosages of thiazolidinedione. Results: We observed that 544 (1.4%) patients developed PD during the follow-up median duration of 6.2 years in patients with newly-diagnosed DM or had a higher risk for PD than patients without DM (HR = 1.150). In the study cohort, the risk of PD was significantly lower in the thiazolidinedione-treated group (HR = 0.399) compared to the non-thiazolidinedione-treated group. Thiazolidinedione reduced the risk of PD in a dose-dependent manner, with HRs ranging from 0.613 to 0.081 with defined daily doses of 0–90 to >720, respectively. Conclusions: Thiazolidinedione use was associated with a significantly reduced risk of PD in patients with newly-diagnosed DM. Further studies to elucidate the common mechanism of PD and DM may provide novel therapies for these two diseases.Key messages Newly-diagnosed diabetes mellitus slightly increases the risk for Parkinson’s disease. Thiazolidinedione is associated with a lower risk of Parkinson's disease in a dose-dependent manner in patients with newly-diagnosed diabetes mellitus.

Original languageEnglish
Pages (from-to)430-436
Number of pages7
JournalAnnals of Medicine
Volume50
Issue number5
DOIs
Publication statusPublished - Jul 4 2018

Keywords

  • Diabetes mellitus
  • National Health Insurance Research Dataset
  • Parkinson’s disease
  • thiazolidinedione

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Association of thiazolidinedione with a lower risk of Parkinson’s disease in a population with newly-diagnosed diabetes mellitus'. Together they form a unique fingerprint.

  • Cite this